- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01013883
The Darlington Retrospective Outpatient Study (DROPSY)
Long Term Outcomes in Patients With Heart Failure
Having heart failure means the heart is unable to pump blood around the body effectively. This reduces life expectancy and hinders normal daily activities. Heart failure affects about one million people in the UK; it is a major cause of death but it is often undetected and under-treated. If diagnosed and treated properly, the symptoms of heart failure can be well controlled and the length and quality of life can be improved.
Two drugs (called ACE-inhibitors and beta-blockers) help patients to live longer and suffer fewer consequences of heart failure. These drugs should be offered to all patients although this does not happen consistently for a variety of reasons. Doctors specialising in heart failure may help patients make better informed decisions about treatments and other aspects of care.
The purpose of this research is to explore the diagnosis, management and outcome of patients with heart failure who are referred to the one stop diagnostic heart failure clinic between Jan 2002 and Dec 2007. This study will provide vital information about diagnosis, initiation and titration of evidence based medication in the hospital, their follow in the primary care and subsequent patient outcome in terms of mortality.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Case notes of all the patients who were referred to the one stop diagnostic heart failure clinic during the period (Jan 2002- Dec 2007) will be reviewed and subjects who were found to have signs and symptoms of the Heart failure will be identified.
This cohort of patients will be further analysed and divided on the basis of Echocardiography (special scan of the heart that looks at the contraction, relaxation, and the flow of blood in the heart chambers) results into two groups.
- Those who have impaired contraction (systolic) function of there Left ventricle (left side chamber of the heart)
- Those who have normal contraction (systolic) function of the left ventricle.
Case notes of these patients will then be studied in detail with regards to their initial presentation, clinical examination, Electrocardiogram (electrical tracing of the heart) and chest X ray (picture of the heart and lungs) report.
These will be co-related with the findings and report of the Echocardiogram.
Once the diagnosis is established, uptake of evidence based medications (beta blockers, ACE inhibitors, spironolactone) and their titration up to the target dose at subsequent follow up visits in the heart failure clinic will be examined.
B) Phase 2 (General practice/ surgery phase)
This part of the study will be conducted at the GP surgery of the identified patient. This will involve accessing the data held at the GP practice with regards to
- Was heart failure treatment continued after discharge from the hospital clinic?
- If medications continued then for how long?
- If medications discontinued then why and by whom (Hospital/GP)?
- Current medications and the doses
- Admissions to the hospital if any?
- Any other co morbidities developed since discharge for the HF clinic?
- Outcome in terms of mortality
- The cause of death as specified on the death certificate
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Durham
-
Darlington, Durham, Vereinigtes Königreich, DL3 6HX
- Darlington Memorial Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- 18 years and over attending heart failure clinic between 01/01/2002- 31/12/07
Exclusion Criteria:
- less than 18 years.
Pregnant females
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
systolic dysfunction
patients having left ventricular systolic dysfunction on echocardiography
|
|
distolic heart failure
patients with clinical heart failure and preserved LV systolic dysfunction
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
All Cause Mortality
Zeitfenster: Patients would be followed up for average of 7 years
|
Patients would be followed up for average of 7 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cardiovascular Mortality
Zeitfenster: Patients would be followed up for average of 7years
|
Patients would be followed up for average of 7years
|
|
|
Admission to Hospital for Any Cause
Zeitfenster: During the follow up period of 7 years
|
Number of patients admitted to the hospital will be recorded
|
During the follow up period of 7 years
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Rajender Singh, MD, county durham and darlington NHS trust
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- RajPh.D2066
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Herzfehler
-
Region SkaneAnmeldung auf EinladungHerzinsuffizienz New York Heart Association (NYHA) Klasse II | Herzinsuffizienz New York Heart Association (NYHA) Klasse IIISchweden
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus... und andere MitarbeiterBeendetHerzinsuffizienz, systolisch | Herzinsuffizienz mit reduzierter Ejektionsfraktion | Herzinsuffizienz New York Heart Association Klasse IV | Herzinsuffizienz New York Heart Association Klasse IIIPolen
-
China National Center for Cardiovascular DiseasesChinese Academy of Medical Sciences, Fuwai HospitalAktiv, nicht rekrutierendLungenentzündung | Sepsis | Infektion | Driveline Heart-assisted Device Related InfectionChina
-
University of WashingtonAmerican Heart AssociationAbgeschlossenHerzinsuffizienz, kongestive | Mitochondriale Veränderung | Herzinsuffizienz New York Heart Association Klasse IVVereinigte Staaten
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Portuguese Association of Interventional CardiologyMedtronicRekrutierungSchwere symptomatische Aortenstenose (definiert als New York Heart Association (NYHA) Klasse ≥ II)Portugal
-
University Hospital, GasthuisbergUnbekanntTransient Left Ventricular Ballooning SyndromeBelgien
-
Medical University of South CarolinaAmerican Heart AssociationAbgeschlossenSingle Ventricle Heart Disease nach Fontan-OperationVereinigte Staaten
-
NYU Langone HealthRekrutierungTako-Tsubo-Kardiomyopathie | Takotsubo-Kardiomyopathie | Broken-Heart-SyndromVereinigte Staaten
-
Mezzion Pharma Co. LtdNational Heart, Lung, and Blood Institute (NHLBI); Pediatric Heart NetworkAbgeschlossenSingle Ventricle Heart Disease nach Fontan-OperationVereinigte Staaten, Kanada